IE51585B1 - Method for the quantitative determination of encainide - Google Patents
Method for the quantitative determination of encainideInfo
- Publication number
- IE51585B1 IE51585B1 IE2621/85A IE262185A IE51585B1 IE 51585 B1 IE51585 B1 IE 51585B1 IE 2621/85 A IE2621/85 A IE 2621/85A IE 262185 A IE262185 A IE 262185A IE 51585 B1 IE51585 B1 IE 51585B1
- Authority
- IE
- Ireland
- Prior art keywords
- encainide
- quantitative determination
- conpound
- metabolites
- caipound
- Prior art date
Links
Landscapes
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
This invention relates to a process for the quantitative determination of ennainide by non-ionic bonding.
According to the invention there is provided a process for the quantitative determination of encainide and the 05 femethyl and 3-nethoxy-O-demethyl metabolites thereof in a biological fluid involving extraction thereof from said fluid and separation thereof by high pressure liquid chromotography cn a silicic acid colum using an organic solvent as mobile phase, wherein said raobiLe phase is the mixture ethanol:water:
BEthanesulfomc acid 500:30:0.1.
Encainide hydrochloride is an antiarrhythric compound which is also referred to in the literature as Ml 9067 (USAN And Ihe USP Dictionary of Drug Names 1980, page 122, United States Harmacopeial Convention, Inc. 12601 Twinhroak Parkway, Rockville, ® 20852, Library of Congress Catalog Card No. 72-88571).
Encainide has the following structural formula.
lbs following publications describe the chemical synthesis of encainide, a number of analogs thereof, and the antiarrhythmic properties of these compounds in animals.
Dykstra, et al., J. Med. Chem., 16 1015-1020 (1973).
Dykstra and Minielli, U.S. Patent No. 3,931,195 patented
January 6, 1976.
Byrne, et al., J. Pharmacology and Bperimental Therapeutics, 5 200, 147-154 (1977).
Assay methods for encainide and its metabolites are disclosed in the following references.
Mayol and Gaitans, Therap. Drug Monitoring, _1, 507-S24 (1979).
Mayol, U.S. Patent Application Serial No. 155,338 filed
June 2, 1980.
In Patent Specification No. ΐ there is described and claimed 4-Hydroxy-3-nethoxy-N-[2-[2-(1methyl-2-piperidinyl )-ethyl j phenyl) benzamide.
Hie structures of encainide and a nurrber of analogs thereof which are described in the foregoing Dykstra, et al. publication and patent are shown in the following table as well as the conpound of Patent Specification No. . The ccnpound nunbers used in the table are the sane as the example nutters enployed in the
Dykstra, et al. patent. Ccnpound No. A is the oonpcund cf Patent
Specification No. ·
Compound No. Bi R3 89 (O-denethylencainide, or CEE) HO- H- ch3- 107 (encainide, or E) CH30- H- ®3- 108 H- CH3O- ch3- 109 CH3O- CH3O- ch3- 139 (N-demethylencainide, or NDE) CH3O- H- H- A (3-methoxy-O-denettol-encainide, or 3-nethoxy ODE) HO- CH3O- CK3-
Caipound Nos. 8S and 139 have been identified by Mayol 10 and Garmans (op. cit.) as metabolites of encainide (Caipound
No. 107) in which publication tbs forner is referred to as ODE anc the latter of NDE. The former (ODE) has been identified as a principal netabolite which is sonEtimss present in plas.iB in amounts several tines the concentration of encainide following treatment with the latter. As a result of an inprovement of the high pressure liquid chromatography assay method described in the iteyol and Ganmans publication, which inprovement constitutes the present invention, it has been found that caipound A is also a principal metabolite of encainide in man following oral administration of the latter, and that it is present in concentrations in the blood plasne substantially greater than that of Caipound Na 89 two or more tours following tha aanir.istration of a 50 mg dose of encainide hydrochloride orally. The HPLC assay method described in the Mayol and Gamnens publication has now been found to have been incapable of distinguishing between Caipound Nos. 89 and Caipound A. It is thought that Caipound A is produced in the body from Caipound No. 89 by a biological transformation process.
For comparative purposes the biological activity of the compounds whose structures are shown in the above table are presented in the following table in which comparative antiarrhythmic activity is given as determined by the laboratory screening test referred to in the Dykstra, et al. paper above.
This is referred to in the table as Test I. Test XI is an approximation of the oral toxicity of these oonpounds in mice, and Tests III and IV refer to the human metabolism results observed following oral administration of an antiarrhythmic oral dose of 75 mg total dose of encainide hydrochloride to patients.
Biological Activity
I Antiarrhythmic activity for ventricular arrhythmia in mice produced by chloroform inhalation; ED50 expressed as mg/kg body weight, intraperitoneal administration,
J.K. Lawson J. Pharmacol. Expt. Ther. 160, 22 (1968).
II ALD50/ATD5O mouse treated orally; ALDjq is the ^proximate lethal dose of half the animals,· ATD50 is the approximate lowest dose where signs of physiologic or neurologic deficit appear in half the animals, expressed as mg/kg body weight.
III Time following oral dosing of humans with 75 mg. of encainide hydrochloride for clearance (plasma concentration <20 ng./ml.) from blood plasma,· hcurs.
TV Approximate half life in hunan blood plasma following
2o oral dosing with encainide hydrochloride; hcurs.
Conpound No. I II III IV 89 1.7-2.8* 25-50/5-10 >16 4-6 107 (encainide) 5.3-15* 50-100/5-10 6 2.5-3 108 10 100/10-25 ♦* 109 10 100/25 «· 139 28 147/15.7 + ♦ A 9.5 250/31.3-62.5 >16 4.6
* Range of various determinations.
” Conpounds have not been administered to man nor observed as metabolites of encainidp in nan or animals.
+ Occurrence in plasma following oral administration of encainide to nan has been rare, and value has not been determinable.
The foregoing results reflect approximately equivalent antiarrhythmic activity for each of these substances except for Conpound No. 89 which is somewhat more potent but also somewhat more toxic in mice. Conpound A differs from and enjoys the advantages over each of Conpound Nos. 89 and 107 of reduced toxicity and of a more prolonged presence in the blood.
EXAMPLE
Assay Procedure
A. Extraction of Biological Fluid.- To 1 ml of plasma cr urine in a screw-capped tube there is added 0.2 ml of 0.5 H.Tris-HCl buffer (2-amino-2-hydroxynethyl-l,3-propanediol), pH 8.5, and 10 ml of n-butyl chloride containing 5% by volume of isopropanol. The sanple is then shaken on an oscillating go muer followed by centrifugation to separate the phases. A 9 ml aliquot of the organic layer is rentjved and evaporated to dryness under a stream of nitrogen and the residue is redissolved in 100 ml of ethanol. A 50 nil aliquot of this solution is injected onto the column for high pressure liquid chronBtography.
B. High Pressure Liquid Chronatography (HPLC) Conditions.A normal phase silicic acid column having dimensions 3.9 nm by 30 cm in length eg lipped with a variable wavelength UV detector set at 254 nm is used. The mobile phase employed consists cf 500 ml of ethanol, 30 ml of water, and 0.1 ml of oethanesulfonic acid at a flow rate of 1 ml per minute. A series of standards containing 0, 25, 100 and 500 ng/ml of each conpound to be assayed was prepared using pooled human plasma. These stand* nte were treated as described above. Quantification of the detector
5158S response was achieved by digital integration or measurement of peak heights. The standard curve for each component was «instructed by linear regression of the detector response versus concentration from the plasma standards. The concentration of coepound in the sanple was then interpolated from these curves
C. Results.- The relative order of elution of encainide and its O-demethjl and 3-rethoxy O-demethyl metabolites from the ociunr anc their retention times is as fellows: Conpound to. 89, 8.3 minutes,- Conpound A, 9.7 minutes; Conpound No. 107,
11·* minutes. The last endogenous plasma oomponent eluted from the colixnn has a retention tire of 3.6 minutes and the baseline is very stable in the region where the metabolites elute. Thus, no interference from endogenous plasma components occurs. Due to differences in extraction efficiencies, specific molar absorptivities, and retention tines for the individual components, the sensitivity of the assay for each of these exponents is as follows: Compound No. 89, 10 ng/ml,· Conpound A, 20 ng/ml; Conpound No. 107, 15 ng/ml.
Claims (2)
1. A process for the quantitative determination of encainide and the O-demsthji and 3-methoxy-O-daiEthyl metabolites thereof in a biological fluid involving extraction thereof from said 5 fluid and separation thereof by high pressure liquid chraratography on a silicic acid column using an organic solvent as mobile phase, wherein said mobile phase is the mixture ethanol: water: nethanesulfonic acid 500:30:0.1 by volume.
2. A process according to claim 1, substantially as herein10 before described.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/188,184 US4332803A (en) | 1980-09-18 | 1980-09-18 | Benzanilide derivative |
IE216085 | 1985-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
IE51585B1 true IE51585B1 (en) | 1987-01-21 |
Family
ID=26319224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE2621/85A IE51585B1 (en) | 1980-09-18 | 1985-10-23 | Method for the quantitative determination of encainide |
Country Status (1)
Country | Link |
---|---|
IE (1) | IE51585B1 (en) |
-
1985
- 1985-10-23 IE IE2621/85A patent/IE51585B1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hammer et al. | Application of isotope derivative technique to assay of secondary amines: estimation of desipramine by acetylation with H3-acetic anhydride | |
Woolf et al. | Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching | |
Rydberg et al. | Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography | |
Winkle et al. | Acebutolol metabolite plasma concentration during chronic oral therapy. | |
Berlin et al. | Micromethod for the determination of diphenylhydantoin in plasma and cerebrospinal fluid—a comparison between a gas chromatographic and a spectrophotometric method | |
Spanggord et al. | Application of high-pressure liquid chromatography and thermal energy analyzer to analysis of trinitroglycerin and its metabolites in blood | |
Manion et al. | High-presure liquid chromatographic assay of theophylline in biological fluids | |
Bach et al. | The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. | |
Madan | Clofibrate Microcapsules II: Effect of wall thickness on release Characteristics | |
IE51585B1 (en) | Method for the quantitative determination of encainide | |
Hoffman et al. | Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs | |
Wu et al. | Capillary column gas chromatographic method using electron-capture detection for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma | |
Winek et al. | Fatal strychnine ingestion | |
Takahashi et al. | Determination of metoclopramide and its glucuronide and sulphase conjugates in human biological fluids (plasma, urine and bile) by ion-pair high-performance liquid chromatography | |
Lister et al. | Methods for the determination of lorazepam and chlordiazepoxide and metabolites in brain tissue: a comparison with plasma concentrations in the rat | |
Ninci et al. | Isothermal gas chromatographic determination of nanogram amounts of chlorimipramine, chlorpromazine and their N-desmethyl metabolites in plasma using nitrogen-selective detection | |
Bruce et al. | Determination of brompheniramine in blood and urine by gas-liquid chromatography | |
Tracqui et al. | Toxicological findings in a fatal case of acebutolol self-poisoning | |
Kirchhoefer et al. | Aspirin—A national survey III: Determination of impurities in bulk aspirin and aspirin formulations by high-pressure liquid chromatography and spectrophotometry | |
Robinson et al. | Tricyclic and tetracyclic antidepressant drugs: forensic toxicology of some autopsy cases | |
Mansour | Determination of pseudoephedrine hydrochloride and carbinoxamine maleate in combination drug formulation by liquid chromatography | |
Maurer | Chromatography of histamine H1-and H2-receptor blockers in biosamples | |
Taylor et al. | The determination of amoxapine in human fatal overdoses | |
Kaistha et al. | Selective determination of tolbutamide in pharmaceutical dosage forms by reaction with ninhydrin | |
Lacroix et al. | Nadolol: High-pressure liquid chromatographic methods for assay, racemate composition and related compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |